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Background: Procalcitonin is useful for the diagnosis of sepsis but its prognostic value regarding mortality is
unclear. This prospective observational study was designed to study the prognostic value of procalcitonin in
prediction of 28 day mortality in patients of sepsis. Fifty-four consecutive patients of sepsis, severe sepsis and septic
shock defined using the 2001 Consensus Conference SCCM/ESICM/ACCP/ATS/SIS criteria from medical Intensive
Care Unit (ICU) of a tertiary care center in New Delhi, India were enrolled from July 2011 to June 2013. Procalcitonin
(PCT), C-reactive protein (CRP) measurements were recorded on day 1, day 7 and day 28 of follow up.
Results: Procalcitonin value was a better predictor of all-cause short-term mortality than C-reactive protein. Those
patients with Procalcitonin levels <7 ng/ml showed higher cumulative survival than those with level [greater than
or equal to]7 ng/ml (69.1% vs. 39.5%, p = 0.02). No such effect was observed in relation to C-reactive protein.
Procalcitonin levels [greater than or equal to]7 ng/ml predicted mortality with a hazard ratio of 2.6(1.1-6.3).
Conclusions: A Procalcitonin value [greater than or equal to]7 ng/ml obtained at the time of admission to the ICU
is a predictor of short-term mortality and thus may allow the identification of those septic patients at increased
mortality risk, and help improve their treatment.
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Sepsis is one of the leading causes of mortality in intensive
care units (ICUs) [1,2]. Prompt diagnosis and administra-
tion of appropriate antimicrobial therapy are essential to
reduce complications associated with sepsis-related organ
failure. However, sepsis response is complex and not all
patients with infections display related signs or symptoms.
The early detection of patients with unfavourable progno-
sis or with an increased risk of mortality is essential in
order to prevent consequent organ dysfunction, which
would increase the degree of complications and hence, pa-
tient mortality.
Procalcitonin (PCT), the 116 amino acids long precur-
sor of calcitonin, is abnormally elevated in sepsis. Procal-
citonin is regarded as a good diagnostic marker of sepsis
in critically ill patients [3]. It has also been evaluated to
shorten the course of antibiotic therapy in septic patients* Correspondence: drsanjeevsinha2002@yahoo.com
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unless otherwise stated.[4]. Serum PCT levels have also been observed to increase
with increasing severity of sepsis and organ dysfunction
[5]. Moreover, administration of PCT to septic animals in-
creases their risk of mortality [6] implying a relationship
between high serum PCT and death. Thus, PCT levels
may contribute to earlier and better stratification of
ICU patients at the risk of death; however the correl-
ation between the level of PCT and the prognosis of sep-
sis is unclear.
The present study was conducted to determine whether
the level of serum PCT, in critically ill subjects with sepsis,




This was a prospective observational study conducted in
the Medical Intensive Care Unit (MICU) of Department
of Medicine at the All India Institute of Medical Sci-
ences (AIIMS) hospital, New Delhi, India from July 2011
to June 2013.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Screening enrolment and follow-up of patients.
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filled the criteria for sepsis laid down by 2001 Consensus
Conference SCCM/ESICM/ACCP/ATS/SIS [1] were en-
rolled. Patients who underwent surgery or trauma during
the previous 72 hours or with chronic kidney disease,
burns, acute pancreatitis, or aged less than 18 years were
excluded (E-protocol). A written informed consent was
obtained from patients or surrogates as specified in the
Institute Ethics Committee, All India Institute of Medical
Sciences, New Delhi approved study protocol.
Study design
Recorded data included demographic characteristics (age
and sex), together with the laboratory test findings (basic
biochemistry, complete blood count, coagulation and arter-
ial blood gases), microbiological culture results, length of
stay in ICU and hospital and outcome. Organ dysfunction
was assessed based on the definitions proposed by the
SCCM/ESICM/ACCP/ATS/SIS consensus conference [1].
Infection was diagnosed by standard clinical, laboratorical
and microbiological parameters. All patients were treated
according to the standard institutional protocol for man-
agement of sepsis and septic shock, based on recommen-
dations from the Surviving Sepsis Campaign [7]. The
duration of antimicrobial therapy was guided by culture
data, site of infection and treating physician. Acute Physi-
ology and Chronic Health Evaluation (APACHE II) score,
Simplified Acute Physiology Score (SAPS II) and Sequen-
tial Organ Failure Assessment (SOFA) scores on day-1 and
procalcitonin (PCT) and C-reactive protein (CRP) levels
on day-1, 7 and 28 of diagnosis of sepsis were calculated.
The endpoint was defined as mortality related to sepsis
within the first 28 days of admission to ICU. The associa-
tions of 28-day mortality with APACHE II and SOFA score
severity, CRP value, and PCT value were examined.
Measurement of biomarkers
Procalcitonin and high sensitivity CRP (hsCRP) were mea-
sured in serum samples that were collected on day-1, 7 and
28 of enrolment. The venous blood (5 mL) was drawn, kept
at room temperature for 2 h and centrifuged at 3000 rpm
for 10 min; and the supernatant was stored at −70°C until
analysis. Serum levels were measured using enzyme linked
immunosorbent assay (ELISA) according to the manufac-
turer’s instruction (RayBiotech, Inc. Norcross, Georgia and
Diagnostic Biochem Canada Inc.).
Statistical analysis
The continuous variables were expressed as the mean ± SD
or as the median and interquartile range (IQR) in the case
of a non-normal distribution. Categorical variables were
summarised as frequencies with percentages in paren-
theses. Quantitative variables at admission were compared
between survivors and non-survivors using Student’s t-testor Wilcoxon rank sum test and qualitative variables by chi-
square test. Comparison of the means of continuous vari-
ables for both the groups was based on analysis of variance
or the nonparametric Kruskal-Wallis test, where indicated.
Based on the day of the death or discharge, Kaplan-Meier
survival analysis was performed. Log rank test was used to
compare the survival between different categories of each
variable. Receiver operating characteristic (ROC) curves
were used to select the optimal cut-offs for procalcitonin,
CRP concentrations and APACHE II, SOFA and SAPS II
scores. Multivariable Cox regression analysis was done to
identify independent predictors of mortality. All of the clin-
ical and laboratory test parameters found by the univari-
able analysis correlated to the end prognosis (in-hospital
mortality) were entered in the model (p < 0.10). An alpha
risk with p < 0.05 was assumed for considering a relation-
ship to be statistically significant. All analyses were per-
formed on Stata software v.11.2.
Results
A total of seventy consecutive patients with sepsis, ad-
mitted to AIIMS MICU were enrolled. Sixteen patients
were excluded based on the exclusion criteria (Figure 1).
Fifty-four patients with sepsis constituted the study
cohort. The mean age was 50.68 ± 18.67 years and 55%
were male. Patients were critically ill with baseline mean
APACHE II, SOFA and SAPS II scores of 24.7, 8.3 and
53.2, respectively. Respiratory tract was the source of
sepsis in majority of cases (71%) followed by genitouri-
nary tract (12%), skin and soft tissue (10%) and abdomen
(9%). Total 55% patients showed positivity in any culture,
whereas 15% in blood culture. Majority of organisms iso-
lated were gram negative (79%). Acinetobacter spp. was the
most common microorganism isolated from tracheal aspi-
rates 10/20 (50%). Klebsiella spp. and Acinetobacter spp.
were the most common microorganisms isolated from
blood culture [2/8 (25%) each] (Table 1).
Table 2 depicts the baseline characteristics of survivors
and non-survivors. The two groups were similar in base-
line characteristics except that the non-survivors had
significantly lower mean blood pressure than that of the




Acinetobacter spp. 2 10 0 0
Klebsiella spp. 4 0 0
Escherichia coli 2 1 2 0
Pseudomonas spp. 0 2 0 0
Enterococcus spp. 1 0 0 0
Staphylococcus aureus 0 1 0 3
Staphylococcus epidermidis 1 0 0 1
Enterobactor spp. 0 1 0 0
Haemophilus influenzae 0 1 0 0
Table 2 Baseline characteristics of patients
Characteristics All patients (n = 54) Ali
Age (years) 50.7 ± 18.7 50.
Male sex 30 (55%) 18
ARDS 22 (41%) 10
Renal dysfunction 31 (57%) 14
Mean BP (mm hg) 78.3 ± 13.7 82.
Temperature (°F) 100.2 ± 1.5 99.
TLC (/cu mm) 17900 (15200–24500) 178
Urea (mg/dL) 65 (52–93) 62
Creatinine (mg/dL) 1.5 (0.8-2.4) 1.0
Prothrombin time (s) 15.1 ± 4.2 13.
Blood sugar (mg/dL) 140.4 ± 63.8 138
pH 7.2 ± 0.1 7.3
Bicarbonate (mmol/L) 22.7 ± 10.1 25.
Albumin (gm/dL) 2.9 ± 0.6 3.0
Lactate (mmol/L) 1.8 (0.8-3.2) 1.2
Positive culture 24 (44%) 13
Positive blood culture 8 (15%) 5 (
Mechanical ventilation 37 (63%) 16
Duration of ICU stay 5 (3–6) 5 (
Duration of hospital stay 10.9 ± 8.1 14.
Procalcitonin (ng/mL) 6.9 (3.6-19.2) 5.4
CRP (mg/dL) 17.6 ± 7.3 20.
SOFA score (Day 1) 8.3 ± 3.7 6.7
APACHE II score (Day 1) 24.7 ± 7.8 21.
SAPS II score (Day 1) 53.2 ± 16.8 47.
Values as mean ± SD or median (interquartile range) or n (percentage); ARDS: Acute
CRP: C-reactive protein; APACHE: Acute physiology and chronic health evaluation; S
function assessment.
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they had higher incidence of renal dysfunction at onset
with 74% vs. 45% (p = 0.03).
All the baseline severity of illness scores (APACHE II,
SOFA, SAPS II) were significantly higher among non-
survivors than that of survivors. Among biochemical
variables, non-survivors had significantly lower levels of
bicarbonate (19.3 ± 8.5 vs. 25.4 ± 10.5 mmol/L; p = 0.02),
deranged prothrombin time (16.96 ± 5.22 vs. 13.74 ±
2.82 s; p < 0.01) and elevated levels of lactate [2.4 (1.3-4.3)
vs. 1.2 (0.8-2.1) mmol/L; p = 0.03] than that of survivors.
Among the biomarkers, levels of serum procalcitonin
were significantly higher in non-survivors compared to
that of survivors [13.1 (6.3-42) vs. 5.38 (3.48-12.8) ng/mL;
p < 0.01] (Figure 2); whereas hsCRP levels did not show
any significant difference between both the groups (21 ±
7.39 vs. 20.10 ± 7.37 mg/dL; p = 0.74) (Figure 1).
Procalcitonin levels were also significantly higher in pa-
tients with septic shock as compared to that with severeve (n = 31) Dead (n = 23) p-value
5 ± 18.3 50.9 ± 19.4 0.94
(58%) 12 (52%) 0.66
(32%) 12 (52%) 0.14
(45%) 17 (74%) 0.03
3 ± 14.06 72.9 ± 11.5 0.01
9 ± 1.2 100.5 ± 1.8 0.17
00 (14400–24500) 19900 (16000–25500) 0.24
(49–75) 76 (61–108) 0.11
0 (0.8-1.8) 1.80 (0.9- 3.6) 0.11
7 ± 2.8 16.9 ± 5.2 0.005
.5 ± 52.1 142.9 ± 78.1 0.80
± 0.13 7.25 ± 0.20 0.38
5 ± 10.4 19.1 ± 8.4 0.02
± 0.6 2.8 ± 0.8 0.25
(0.8-2.1) 2.4 (1.3-4.3) 0.01
(42%) 11 (48%) 0.66
16%) 3 (13%) 0.75
(52%) 21 (91%) 0.002
4–6) 4 (3–5) 0.75
6 ± 6.1 5.1 ± 3.5 0.001
(3.5-12.8) 13.1 (6.3-42) 0.008
1 ± 7.4 21 ± 7.4 0.76
± 3.4 10.5 ± 3.2 0.0001
9 ± 7.1 28.6 ± 7.1 0.001
0 ± 14.9 61.5 ± 15.8 0.001
respiratory distress syndrome; ICU: Intensive Care Unit; BP: Blood pressure;
APS: Simplified acute physiology score; SOFA: Sequential organ
Figure 2 Comparison of procalcitonin between survivors and
non survivors on day-1. Data are presented as box plots with
median lines, 25- and 75-percentile boxes, and 10- and 90-percentile
error bars. The stars represent the outliers.
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sis (34.6 ± 36.7 vs. 3.8 ± 1.6 ng/mL; p = 0.008) (Figure 3).
The level of procalcitonin decreased significantly in sur-
vivors over 28 days. The median of procalcitonin fell from
5.4 ng/mL on day-1 to 3.1 ng/mL on day-7 (p = 0.002) to
0.1 ng/mL on day-28 (p = 0.01) (Figure 3).
Also the level of hsCRP decreased among survivors
over 28 days. Mean hsCRP fell from 17.3 mg/dL on day-
1 to 14.5 mg/dL on day-7 (p = 0.02) to 4.8 mg/dL on
day-28 (p < 0.01) (Figure 2).
The 28-day mortality in the present study was 43%.










Day 1 Day 7 Day 28
Figure 3 Trend of serum procalcitonin over 28 days in
survivors. Data presented as line graph with dots as median and
error bars as interquartile range.followed by severe sepsis (41%) and sepsis (4%). Baseline
variables that predicted mortality in univariable analysis
included renal dysfunction, low mean blood pressure,
APACHE II, SOFA, SAPS II score, serum lactate and
serum procalcitonin.
In multivariate analysis, only APACHE II score at the
time of admission was found to be an independent pre-
dictor of mortality (p = 0.005; HR 3.4(1.4-9.6)).
Discussion
Despite advances in medical science and antibiotic ther-
apy, sepsis remains a major cause of morbidity and mor-
tality in ICU. In the present study, the mortality due to
sepsis was 43%; the overall mortality observed in this
study was consistent with the reported wide range (18%
to 56%) of overall mortality due to sepsis [8,9]. Also mor-
tality increased with severity of sepsis, the maximum be-
ing due to septic shock (61%) which was similar to the
rates reported in previous studies [9,10].
The place of study being a predominantly respiratory
care ICU, lower respiratory tract was the most common
source of infection (71%). Fifty-five percent of the sub-
jects had culture positivity which is comparable with
previous reports; [11] but relatively lower values have
also been reported [9,12]. Blood culture positivity was
only 15%, which is relatively lower than previous reports
[12,13]. One possible explanation for this difference could
be the fact that this institute is a tertiary care centre in a
large city and hence some of the patients are delayed re-
ferrals, where most of them having already received antibi-
otics prior to admission. The majority of microorganisms
isolated were gram negative in nature with Acinetobacter
spp. being the most commonly identified (35%). This
could be due to the clinic being predominately respiratory
care ICU and a tertiary care hospital attending predomin-
antly the patients who already have received primary care.
Culture positivity was not predictive of prognosis (p =
0.66; HR 0.84 (0.37-1.90)). This finding is similar to pre-
vious studies that did not establish culture positivity as a
predictor of mortality [2,14].
In this study, it was observed based on univariable
analysis, a serum procalcitonin level ≥7 ng/mL on day-1
predicted mortality (HR 2.5(1.1-6.2); p = 0.02). This find-
ing corroborates the findings of earlier studies by Meng
et al. and Clec’h et al. [15,16]. On the contrary, some stud-
ies did not find procalcitonin to predict mortality [17-20];
the differences could be due to the fact that this study was
conducted in an exclusive medical ICU, thereby excluding
surgical and post traumatic patients who might have a
spurious increase in procalcitonin [16,21] as compared
to mixed ICU populations in some studies [17-19]. In
addition, since most of the microorganisms isolated were
gram negative, a gram negative septicaemia has been
found to be better correlated with serum procalcitonin
Figure 5 ROC curve analysis for Procalcitonin.
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citonin declined significantly in survivors over the course
of 28 days. Several studies [17,24,25] have implicated the
levels of procalcitonin to be a good predictor of prognosis
in sepsis; however this could not be compared with that of
non-survivors since their median survival was 4 (3–5)
days. This might be due to the fact that this study popula-
tion was sicker with a mean APACHE II score of 28 in
non-survivors. This difference could not have been due to
the care provided in the ICU as the duration of stay in
ICU of survivors and non-survivors was similar [5(4–6)
vs. 4(3–5) days; p = 0.75]. Moreover, patients in both the
groups were treated by the same group of physicians ac-
cording to the institution protocol based on surviving sep-
sis guidelines [26]. It was also observed that the level of
serum procalcitonin increases with severity of sepsis and
organ dysfunction which could also be used to identify
patients with higher risk of adverse outcomes. These
findings are similar to that reported by Giamarellos-
Baorboulis et al. [5] (Figures 4 and 5).
On the contrary, no significant differences between
levels of hsCRP were observed in two groups and also
hsCRP did not predict mortality in sepsis. This finding is
supported by previous studies [15,25,27,28]. It was also
found that the level of hsCRP fell over the course of in-
hospital stay in survivors which might be due to the fact
that CRP is an acute inflammatory reactant and its levels
improve with time (Figure 6).
The APACHE II, SOFA and SAPS II scores (APACHE
II ≥ 24, SAPS II ≥ 51, and SOFA ≥ 9) computed from the
baseline variables were found to be predictors of mortal-
ity in univariable analysis. APACHE II score was an in-
dependent predictor of mortality in multivariate analysis
[p = 0.005; HR 3.4(1.4-9.6)].
This study is significant based on the following merits.












Figure 4 Kaplan Meier survival analyses for Procalcitonin.thereby excluding post surgical trauma cases which have
been shown to spuriously increase levels of procalcito-
nin. The markers were repeated at regular intervals to
determine the trend in the course of markers.
Some of the limitations of this study include this being a
single centre study with a relatively small sample size and
majority of patients were receiving course of antibiotics
prior to admission. The levels of procalcitonin were mea-
sured using an ELISA based assay which is relatively lessFigure 6 ROC curve analyses for CRP.
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(TRACE) technology in which the duration of assay is
rapid (19 min) but expensive [29]. Levels of procalcitonin
were measured only at three points in the course of the
study and also the levels of procalcitonin and hsCRP could
not be compared on serial measurements due to early
mortality. Moreover, weekly measurements of procalcito-
nin cannot guide antibiotic therapy.Conclusions
In conclusion, it has been observed that despite the use
of optimal support and better strategy, the mortality rate
in sepsis still remains high (56.2%). Elevated level of pro-
calcitonin at admission is a better predictor of mortality
than high sensitivity CRP that helps in the stratification
of patients and to identify patients at higher risk of ad-
verse outcomes. However, markers are recommended to
be considered only in conjunction with clinical history
and physical examination and in the light of experience.
Furthermore, a comprehensive knowledge of the biology,
advantages and limitations of markers is imperative be-
fore applying them as a routine clinical tool with prog-
nostic value. A future randomised control study of PCT
and non-PCT monitored patients could determine if
outcome and cost benefits accrue with PCT use.
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